DongKoo Bio&Pharma Co. Ltd
DongKoo Bio&Pharma. Co., Ltd. researches, develops, manufactures, and sells medicines in South Korea. The company offers prescribed medicines, such as liver disease, skeletal muscle relaxant, endocrine system, brain nervous system, urogenital, antiobestic, digestive system, circulatory organ, allergenic, mental disease, oral dermatology, external preparation of dermatology, antiseptic, antiviral,… Read more
DongKoo Bio&Pharma Co. Ltd (006620) - Net Assets
Latest net assets as of September 2025: ₩110.66 Billion KRW
Based on the latest financial reports, DongKoo Bio&Pharma Co. Ltd (006620) has net assets worth ₩110.66 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩269.00 Billion) and total liabilities (₩158.34 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩110.66 Billion |
| % of Total Assets | 41.14% |
| Annual Growth Rate | 51.19% |
| 5-Year Change | 11.28% |
| 10-Year Change | N/A |
| Growth Volatility | 234.37 |
DongKoo Bio&Pharma Co. Ltd - Net Assets Trend (2015–2024)
This chart illustrates how DongKoo Bio&Pharma Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for DongKoo Bio&Pharma Co. Ltd (2015–2024)
The table below shows the annual net assets of DongKoo Bio&Pharma Co. Ltd from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩105.33 Billion | -4.63% |
| 2023-12-31 | ₩110.44 Billion | +8.17% |
| 2022-12-31 | ₩102.11 Billion | +1.98% |
| 2021-12-31 | ₩100.12 Billion | +5.78% |
| 2020-12-31 | ₩94.65 Billion | +10.51% |
| 2019-12-31 | ₩85.65 Billion | +18.80% |
| 2018-12-31 | ₩72.10 Billion | +91.01% |
| 2017-12-31 | ₩37.74 Billion | +71.22% |
| 2016-12-31 | ₩22.05 Billion | +764.45% |
| 2015-12-31 | ₩2.55 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to DongKoo Bio&Pharma Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 6794160444000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩67.32 Billion | 63.91% |
| Common Stock | ₩14.23 Billion | 13.51% |
| Other Components | ₩23.78 Billion | 22.58% |
| Total Equity | ₩105.33 Billion | 100.00% |
DongKoo Bio&Pharma Co. Ltd Competitors by Market Cap
The table below lists competitors of DongKoo Bio&Pharma Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Elixir Energy Ltd
AU:EXR
|
$57.78 Million |
|
Intellistake Technologies Corp.
F:E41
|
$57.79 Million |
|
GATELEY (HLDGS) LS -10
F:5I2
|
$57.81 Million |
|
Srisawad Capital 1969 PCL
BK:SCAP
|
$57.82 Million |
|
PLIANT THERA.INC.DL-0001
F:9PT
|
$57.71 Million |
|
Türk Traktör ve Ziraat Makineleri A.S
PINK:TTRKF
|
$57.71 Million |
|
UHT Unitech Co., Ltd.
TWO:6618
|
$57.70 Million |
|
Bright Scholar Education Holdings Ltd Class A
NYSE:BEDU
|
$57.66 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in DongKoo Bio&Pharma Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 110,399,968,690 to 105,331,586,000, a change of -5,068,382,690 (-4.6%).
- Net income of 2,035,535,450 contributed positively to equity growth.
- Dividend payments of 3,312,577,450 reduced retained earnings.
- Share repurchases of 3,407,712,920 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩2.04 Billion | +1.93% |
| Dividends Paid | ₩3.31 Billion | -3.14% |
| Share Repurchases | ₩3.41 Billion | -3.24% |
| Other Changes | ₩-383.63 Million | -0.36% |
| Total Change | ₩- | -4.59% |
Book Value vs Market Value Analysis
This analysis compares DongKoo Bio&Pharma Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.42x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 5.03x to 1.42x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩1080.29 | ₩5430.00 | x |
| 2017-12-31 | ₩1656.17 | ₩5430.00 | x |
| 2018-12-31 | ₩2509.16 | ₩5430.00 | x |
| 2019-12-31 | ₩3027.49 | ₩5430.00 | x |
| 2020-12-31 | ₩3345.60 | ₩5430.00 | x |
| 2021-12-31 | ₩3570.78 | ₩5430.00 | x |
| 2022-12-31 | ₩3696.33 | ₩5430.00 | x |
| 2023-12-31 | ₩3996.59 | ₩5430.00 | x |
| 2024-12-31 | ₩3815.25 | ₩5430.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently DongKoo Bio&Pharma Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.93%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.82%
- • Asset Turnover: 1.02x
- • Equity Multiplier: 2.32x
- Recent ROE (1.93%) is below the historical average (29.86%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 158.01% | 5.01% | 1.32x | 23.83x | ₩3.77 Billion |
| 2016 | 49.50% | 12.49% | 1.34x | 2.96x | ₩8.71 Billion |
| 2017 | 28.99% | 10.82% | 1.34x | 2.00x | ₩7.17 Billion |
| 2018 | 6.34% | 4.36% | 1.01x | 1.45x | ₩-2.64 Billion |
| 2019 | 17.63% | 12.06% | 0.94x | 1.55x | ₩6.54 Billion |
| 2020 | 9.66% | 6.57% | 0.96x | 1.53x | ₩-324.82 Million |
| 2021 | 9.32% | 6.01% | 1.00x | 1.55x | ₩-685.84 Million |
| 2022 | 6.48% | 3.39% | 1.13x | 1.69x | ₩-3.60 Billion |
| 2023 | 10.70% | 5.48% | 1.13x | 1.73x | ₩771.64 Million |
| 2024 | 1.93% | 0.82% | 1.02x | 2.32x | ₩-8.50 Billion |
Industry Comparison
This section compares DongKoo Bio&Pharma Co. Ltd's net assets metrics with peer companies in the Pharmaceuticals industry.
Industry Context
- Industry: Pharmaceuticals
- Average net assets among peers: $96,368,028,169
- Average return on equity (ROE) among peers: -11.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| DongKoo Bio&Pharma Co. Ltd (006620) | ₩110.66 Billion | 158.01% | 1.43x | $57.77 Million |
| Sam Chun Dang Pharm. Co. Ltd (000250) | $114.32 Billion | 10.17% | 0.61x | $3.69 Billion |
| NatureCell Co.Ltd (007390) | $34.02 Billion | -9.48% | 0.55x | $37.82 Million |
| Sam-A Pharm. Co. Ltd (009300) | $148.92 Billion | 6.63% | 0.09x | $21.27 Million |
| Kyung Dong Pharmaceutical Co. Ltd (011040) | $257.20 Billion | 4.73% | 0.21x | $50.06 Million |
| WooGene B&G Co. Ltd (018620) | $26.51 Billion | -25.02% | 1.26x | $10.61 Million |
| Oscotec Inc (039200) | $28.83 Billion | -91.10% | 0.70x | $890.75 Million |
| EstechPharma Co. Ltd (041910) | $123.30 Billion | 5.58% | 0.09x | $50.99 Million |
| Komipharm International Co. Ltd (041960) | $93.39 Billion | -15.32% | 0.50x | $237.27 Million |
| Eagle Veterinary Technology Co.Ltd (044960) | $40.83 Billion | 8.91% | 0.29x | $20.48 Million |